The United Kingdom and the United States have reached a landmark bilateral deal that will maintain zero duties on British drug shipments going into the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to raise spending on medicines through the NHS. This commitment secures that duties on these key products will remain at zero for a duration of three years.
This deal comes after previous warnings to significantly raise duties on patented pharmaceutical products, with increases mentioned up to double the cost.
"This deal with the Britain strengthens the global environment for innovative medicines and introduces much-needed fairness to American-British medicine commerce," an announcement declared.
Economic Significance
Medicines are one of the Britain's largest exports to the US, which is clearly the primary market for large British pharmaceutical firms.
Export figures show that in the one-year period prior to the third quarter, the UK sold drugs worth billions to the US. This figure made up a significant portion of all goods exports in that timeframe.
"This guarantee secures employment, increases funding and facilitates the UK to establish itself as a international leader for life sciences," a government official commented.
Detailed UK Commitments
The pact includes several key commitments from the British government:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to double overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be capped at fifteen percent. In the past, rebates topped twenty percent.
Broader Context
The deal follows a ongoing tension between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
This friction were intensified by arguments that American customers were charged several times more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or scrapped, while substantial funding commitments have been announced toward US facilities.
A senior figure publicly accepted that the NHS had to invest a greater share on medicines, noting that its spending on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
